Taste-masked quinine sulphate pellets: Bio-availability in adults and steady-state plasma concentrations in children with uncomplicated Plasmodium falciparum malaria

Annals of Tropical Paediatrics

Volumn 28, Issue 2, 2008, Pages 103-109

  Kayumba, P C ^a,b   Twagirumukiza, M ^a,c   Huyghebaert, N ^b   Ntawukuliryayo, J D ^a   Van Bortel, L ^c   Vervaet, C ^d   Remon, Jean Paul ^b  

^a UNIVERSITY OF RWANDA   (Rwanda)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

QUININE SULFATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BITTER TASTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANTIMALARIALS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; QUININE; TABLETS; TASTE;

EID: 48749103251     PISSN: 02724936     EISSN: None     Source Type: Journal    
DOI: 10.1179/146532808X302116     Document Type: Article

References (17)

1. Bloland PB. Drug Resistance in Malaria. WHO/CDS/DRS/2001.4. http://www.cdc.gov/malaria/pdf/bloland_WHO2001.pdf (accessed 20/06/07).
2. World Health Organization. WHO/FCH/CAH/00.1. Management of the Child with a Serious Infection or Severe Malnutrition: Guidelines for Care at the First-Referral Level in Developing Countries. Appendix 2, p 139. http://www.who.int/child-adolescenthealth/publications/ referral_care/Referral_Care_en.pdf (accessed 20/06/07).
3. Kayumba PC, Huyghebaert N, Ntawukuliryayo JD, Vervaet C, Remon JP. Impact du cassage de comprimés de sulfate de quinine sur l'exactitude de la dose administrée aux enfants. Pharmacien d'Afrique 2006; 193:11-16.
4. Kayumba PC, Huyghebaert N, Ntawukuliryayo JD, Vervaet C, Remon JP. Quinine sulphate pellets for flexible pediatric drug dosing: Formulation development and evaluation of taste-masking efficiency using the electronic tongue. Eur J Pharm Biopharm 2007; 66:460-5
5. International Committee on Harmonization (ICH). CPMP/ICH/2711/99. Topic E 11. Clinical Investigation of Medicinal Products in the Pediatric Population. http://www.emea.europa.eu/pdfs/human/ich/ 271199en.pdf (accessed 20/06/07).
6. Salako LA, Sowunmi A. Disposition of quinine in plasma, red cells and saliva after oral and intravenous administration to healthy adult Africans. Eur J Clin Pharmacol 1992; 42:171-4.
7. Samanidou VF, Evaggelopoulou EN, Papadoyannis IN. Simultaneous determination of quinine and chloroquine anti-malarial agents in pharmaceutical and biological fluids by HPLC and fluorescence detection. J Pharm Biopharm Anal 2005; 38:21-8.
8. McCalley DV. Analysis of the cinchona alkaloids by high-performance liquid chromatography and other separation techniques. J Chromat A 2002; 967:1-19.
9. FDA Guidance for Industry. Bioanalytical Method Validation. Rockville, MD: Food and Drug Administration Centre for Drug Evaluation and Research, 2001. http://www.fda.gov/cder/guidance/index.htm (accessed 15/06/07).
10. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical complications. Clin Pharmacokinet 1996; 31:263-99.
11. Lebrun-Vigne B. Les antimalariques: Pharmacologie, pharmacocinétique et toxicité chez l'adulte. Méd Mal Infect 1999; 29:229-48.
12. Auprayoon P, Sukontason K, Na-Bangchang K, et al. Pharmacokinetics of quinine in chronic liver disease. Br J Clin Pharmacol 1995; 40:494-7.
13. Wanwimolruk S, Chalroft S. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. Br J Clin Pharmacol 1991; 32:617-20.
14. Van Hensbroek MB, Kwiatkowski D, van den Berg B, Hoek FJ, van Boxtel CJ, Kager PA. Quinine pharmacokinetics in young children with severe malaria. Am J Trop Med Hyg 1996; 54:237-42.
15. White NJ. Current concepts: The treatment of malaria. N Engl J Med 1996; 335:800-6.
16. Pukrittayakamee S, Wanwimolruk S, Stepniewska K, et al. Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob Agents Chemother 2003; 47: 3458-63.
17. Barennes H, Sterlingot H, Nagot N, et al. Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria. Eur J Clin Pharmacol 2003; 58:649-52